{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.16","upperLimit":"48.27","value":"35.18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"Will be assessed by the Response Evaluation Criteria in Solid Tumors version 1.1 and Disease Control (see section 9.3.2 of the ADVL1622 Protocol). Response + Disease Control rate will be calculated as the percent of evaluable patients who are responders or who met the definition of disease control, and confidence intervals will be constructed accounting for the two-stage design.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Osteosarcoma"}],"paramType":"NUMBER","populationDescription":"All patients who met the evaluable for response criteria outlined in section 9.4 of the ADVL1622 protocol in the osteosarcoma stratum.","reportingStatus":"POSTED","timeFrame":"Up to the first 6 cycles of therapy.","title":"Objective Response (Osteosarcoma Stratum)","type":"PRIMARY","unitOfMeasure":"Percentage of patients"}